Levelling Up Indonesia's Clinical Trial Capabilities

DATE : **Wednesday, April 12, 2023**
TIME : **13.00 p.m. – 17.30 p.m. WIB**
VENUE : **Retreat Lounge, 1st Floor, The Westin Jakarta**

Time (WIB)	Activity	
	Offline	**Online**
12.00 – 13.00	*Attendees' arrival, open registration*	*Test room, technical set up for speakers and team*
12.45 – 13.00	VO MC the event will start shortly	
13.00 – 13.05	• Opening by MC • National Anthem – INDONESIA RAYA	
13.05 - 13.10	Welcoming speech by **Dr. Dra. Lucia Rizka Andalucia, Apt, M.Pharm, MARS,** Director General of Pharmaceutical and Medical Devices, Ministry of Health, Republic of Indonesia	
13.10 - 13.15	• MC invite moderator for 1st panel discussion • Moderator opening session 1 • Topic overview and speakers introduction by Moderator • Moderator: **Roy Himawan, S. Farm., Apt., M.K.M.**, Director for the pharmaceutical and medical advice resilience directorate, Ministry of Health, Republic of Indonesia	
Session I: The required ecosystem and policy needs of multinational clinical trial sponsors		
13.15 – 13.25	**Alexander Schmidt**, Head of Vaccine Development at the Bill and Melinda Gates Medical Research Institute (MRI) Topic : Location selection and barriers to implementing (multi-center, multi-national) CT from a clinical/clinical operations point of view.	
13.25 – 13.35	**Q & A with Alexander Schmidt**	
13.35 – 13.45	**Hannah Woo**, Head, Vaccines Real World Evidence Generation Program Operations, Takeda Vaccines Business Unit, Singapore Topic : What multinationals look for in countries when planning clinical trial programs. Best practices and challenges.	
13.45 – 13.55	**Dr. Samuel Lim,** Clinical Research Associate Manager**,** Novartis Topic : What multinationals look for in countries when planning clinical trial programs. Best practices and challenges.	
13.55 – 14.05	**Prof. Dr. Herkutanto, LL.M**, Chair Data and Material Transfer Reviewer, Ministry of Health, Republic of Indonesia Topic : Advocating Clinical Trials in Indonesia: the challenges and potential solutions	
14.05 – 14.20	**Q & A**	
14.20 – 14.25	• Conclusion by Moderator	
14.25 – 14.30	• Moderator invite MC • MC closing session I	
14.30 – 14.35	• Opening by MC • MC invite moderator for 2nd panel discussion • Moderator opening session 2 • Topic overview and speakers introduction by Moderator	

	• Moderator: **dr. Sunarto**, M.Kes, Acting Director of Healthcare Service Governance
Session II: Improving the clinical trial environment	
14.35 – 14.45	**Audrey Ooi,** Head of Business Development**,** Clinical Research Malaysia Topic : Best practices in facilitating clinical trials in Malaysia.
14.45 – 14.55	**Dr. Carole Wallis**, Scientist, BARC SA, Division of Lancet Laboratories (pty) Ltd., CERBA, South Africa Topic : What is needed from a technology, infrastructure, policy and human resources perspective to manage a world class central lab?
14.55 – 16.05	**Dr. Trudie Lang**, Head of Global Health Networ, Professor of Global Health Research (Oxford) Topic : Capacity development and clinical research process improvement, lesson learned in low and lower-middle income countries
16.05 – 16.15	**Prof. Dr. dr. Sri Rezeki Hadinegoro SpA(K)**, Chairwoman of Indonesia Technical Advisory Group on Immunization (ITAGI) Topic : Experience on Vaccine Clinical Research
16.15 – 16.25	**dr. Muhammad Karyana, M.Kes,** Network Director/National Institute of Health Research & Development of Indonesia Research Partnership on Infectious Desease (INA-RESPOND) Topic : Readiness of Health Ministry to facilitate clinical trials (including the INA-RESPOND network)
16.25 - 16.45	**Q & A**
16.45 – 16.50	• Conclusion by Moderator • Moderator invite MC • MC closing session II and the whole event

Should you have any questions or require further information, please contact the committee to clinicaltrial@tenggara.id or Ms. Yessy Rizky at yessy@tenggara.id or WhatsApp at +62 813-1743-5680 or Mr. Irvan Iswaraputra at irvan@tenggara.id or WhatsApp at +62 812-2356-7594.

Don’t miss out on this valuable opportunity to learn and grow in your field.